Gene and cell Therapy (GMP grade)

#GMP-CD47, Recombinant Human IL-7

#GMP-CD47, Recombinant Human IL-7

Interleukin-7 (IL-7), a member of the cytokine family related to IL-2, stimulates the survival, proliferation, and homeostasis of T cells via the gamma c (γc) subunit of the receptor.
  • 生物活性_IL7.jpg
  • 產品穩定性_IL7.jpg
詳細介紹

#GMP-CD47, Recombinant Human IL-7

白細胞介素7(Interleukin-7, IL-7)是IL-2相關細胞因數家族的一員,通過受體的γ c(gamma c)亞單位,刺激T細胞的存活、增殖與平衡。IL-7可替代IL-2用於T細胞活化,並可避免IL-2對Treg的啟動引起的免疫耐受。有研究表明IL-7在注射疫苗或細胞治療中可擴增抗原特異性T細胞;IL-7也能夠促進化療或造血幹細胞移植後的T細胞恢復。
重組人IL-7蛋白由哺乳動物細胞表達,採用無動物源性材料生產和藥用輔料製劑。執行《藥品生產品質管制規範(2010年修訂)》,嚴格控制細菌內毒素殘留、宿主蛋白質殘留、外源性DNA殘留等,保證產品品質安全有效。


產品用途
可用於多種體外細胞培養。
IL-7可替代IL-2(Cat.No: GMP-C013)用於T細胞活化,並可避免IL-2對Treg的啟動引起的免疫耐受。

保存條件
 -20℃,有效期見瓶身
生物活性-Cell Based Assay

Measured in a cell proliferation assay using PHA-activated human peripheral blood lymphocytes (PBL).The specific activity of Recombinant human IL-7 is 1.0 × 108 IU/mg, which is calibrated against human IL-7 WHO International Standard (NIBSC code: 90/530)
The activity of GMP Human IL-15 Protein(Cat. No.:GMP-C016) was compared to another commercially available product

產品穩定性

產品僅供科研或生產使用,不可直接應用於人體。

Quality Control
Item Standard
Appearance White porosity
Reconstitution Totally dissolve in stated time
Visible particle Conform to ChP
pH value 6.9–7.9
Purity 95%
Bioactivity 2.0×106 IU/mg
Endotoxin < 10 EU/mg
Host protein 0.005%
Exogenous DNA residue 100 pg/mg
Mycoplasma test Negative
Sterility test Conform to ChP
相關產品
Cat# Product
GMP-C070 Recombinant Human IL-1 alpha
GMP-CG93 Recombinant Human IL-1 beta
GMP-C013 Recombinant Human IL-2
GMP-CD03 Recombinant Human IL-4
GMP-C009 Recombinant Human IL-6
GMP-CD47 Recombinant Human IL-7
GMP-CI58 Recombinant Human IL-12
GMP-CD72 Recombinant Human IL-18
GMP-CC45 Recombinant Human IL-21
GMP-CC79 Recombinant Human GM-CSF
產品文獻
Title Author Year Journal Title
T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape Dai, Zhenyu, Mu, Wei, Zhao, Ya, Cheng, Jiali, Lin, Haolong, Ouyang, Kedong, Jia, Xiangyin, Liu, Jianwei, Wei, Qiaoe, Wang, Meng, Liu, Chaohong, Tan, Taochao, Zhou, Jianfeng
2022
Signal Transduction and Targeted Therapy
Signaling Dynamics of TSHR-Specific CAR-T Cells Revealed by FRET-Based Biosensors. Jing Zhou, Jiangqing Chen, Yanjie Huang, Xiaofei Gao, Chun Zhou, Xianhui Meng and Jie Sun 2022 Frontiers in Cell and Developmental Biology
Identification of cytotoxic T cells and their T cell receptor sequences targeting COVID-19 using MHC class I-binding peptides Hikichi, Tetsuro, Sakamoto, Michiko, Harada, Makiko, Saito, Maki, Yamane, Yuka, Tokumura, Kimihisa, Nakamura, Yusuke 2022 Journal Of Human Genetics
MUC1-Tn-targeting chimeric antigen receptor-modified Vγ9Vδ2 T cells with enhanced antigen-specific anti-tumor activity Xiaochen Zhai, Fengtao You, Shufen Xiang, Licui Jiang, Dan Chen, Yafen Li, Shuangshuang Fan, Zhichao Han, Tingting Zhang, Gangli An, Bozhen Zhang, Yusheng Chen, Huimin Meng, Lin Yang 2021 American Journal of Cancer Research
The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domains Zhenyu Dai, Wei Mu, Ya Zhao, Xiangyin Jia, Jianwei Liu, Qiaoe Wei, Taochao Tan, Jianfeng Zhou 2021 MOLECULAR THERAPY
Cas9-Cleavage Sequences in Size-Reduced Plasmids Enhance Nonviral Genome Targeting of CARs in Primary Human T Cells Ruirui Jing, Peng Jiao, Jiangqing Chen, Xianhui Meng, Xiaoyan Wu, Yanting Duan, Kai Shang, Liling Qian, Yanjie Huang, Junwei Liu, Tao Huang, Jin Jin, Wei Chen, Xun Zeng, Weiwei Yin, Xiaofei Gao, Chun Zhou, Michel Sadelain, Jie Sun 2021 Small Methods